Platelet Dysfunction in Blood Donors
Conditions
Keywords
platelets, bleeding
Brief summary
Platelets are circulating blood cells. They bind to each other and to the damaged vessel wall to prevent excessive bllod loss. Unlike quantitative platelet defects, there is no automated, simple test to diagnose qualitative platelets defects. However, these defects expose to bleeding in a surgical situation and could explain the transfusion inefficiency of some platelet concentrates. In recent decades, considerable progress has been made in understanding qualitative platelet disorders. In this project, we propose to submit blood donors to a standardized hemorrhagic diathesis questionnaire and to compare the prevalence of platelet function abnormalities in blood donors with and without hemorrhagic diathesis.
Detailed description
Primary objective specify the prevalence of qualitative platelet disorders in blood donors with i) a clinical history of bleeding diathesis collected through a standardized and validated questionnaire ii) and / or a hematoma (more than 4 cm) that occurred during blood donation. Secondary objectives to obtain the prevalence of other defects of hemostasis
Interventions
BIOLOGICALsample
confirmation of platelet dysfunction
Sponsors
University of Marseille
Etablissement Français du Sang
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Intervention model description
prospective case control
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
\- Any male or female volunteer eligible for the blood donation
Exclusion criteria
* Subject with contraindications to blood donation: * weight \<50 kg; * severe fatigue, * anemia, * insulin-dependent diabetes; * subject treated for epileptic seizures or having followed a treatment whose arrest is less than 14 days old. * active pregnancy or childbirth less than 6 months old. * viral disease (eg influenza, gastroenteritis ...) active less than two weeks after the end of symptoms. * waiting period not respected after certain acts of daily life according to the regulatory criteria set by the EFS * HIV infection, hepatitis B, hepatitis C
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Platelet functions | first visit 1 week | Quantification of surface platelet proteins by flow cytometry |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Exploration of Coagulation | first visit 1 week | Von Willebrand factor quantification |
Countries
France
Outcome results
None listed